{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:34:08Z","timestamp":1762353248867,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.beha.2022.101380","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T07:50:38Z","timestamp":1663141838000},"page":"101380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis"],"prefix":"10.1016","volume":"35","author":[{"given":"Deepti H.","family":"Radia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mufaddal T.","family":"Moonim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.beha.2022.101380_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/17474086.2014.955008","article-title":"The serum tryptase test: an emerging robust biomarker in clinical hematology","volume":"7","author":"Valent","year":"2014","journal-title":"Expet Rev Hematol"},{"issue":"12","key":"10.1016\/j.beha.2022.101380_bib2","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.beha.2022.101380_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20% 1 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.beha.2022.101380_bib4","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/modpathol.2011.84","article-title":"Evaluation of the WHO criteria for the classification of patients with mastocytosis","volume":"24","author":"Sanchez-Munoz","year":"2011","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.beha.2022.101380_bib5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2022.101380_bib6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2017.277897","article-title":"Digital PCR: a sensitive and precise method for KIT D816V quantification in mastocytosis","volume":"64","author":"Greiner","year":"2018","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.beha.2022.101380_bib7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23672","article-title":"Mastocytosis Centre, Odense University Hospital (MastOUH). Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis","volume":"89","author":"Kristensen","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2022.101380_bib8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3324\/haematol.2019.217950","article-title":"Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis","volume":"105","author":"Greiner","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.beha.2022.101380_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101380_bib10","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.beha.2022.101380_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.beha.2022.101380_bib12","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.beha.2022.101380_bib13","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2022.101380_bib14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.beha.2022.101380_bib15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2018886507","article-title":"Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis","volume":"134","author":"Mu\u00f1oz-Gonzalez","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2022.101380_bib16","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2022.101380_bib17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(1) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2022.101380_bib18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.13865","article-title":"ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis","volume":"175","author":"Pardanani","year":"2016","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.beha.2022.101380_bib19","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/bloodadvances.2018020628","article-title":"Impact of somatic and germline mutations on the outcome of systemic mastocytosis","volume":"2","author":"Mu\u00f1oz-Gonzalez","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.beha.2022.101380_bib20","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2018886507","article-title":"Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis","volume":"134","author":"Mu\u00f1oz-Gonzalez","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2022.101380_bib21","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"issue":"21","key":"10.1016\/j.beha.2022.101380_bib22","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/bloodadvances.2018026245","article-title":"Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models","volume":"2","author":"Pardanani","year":"2018","journal-title":"Blood Adv"},{"issue":"31","key":"10.1016\/j.beha.2022.101380_bib23","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: mutation-adjusted risk score for advanced systemic mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2022.101380_bib24","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(20)30400-2","article-title":"Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study","volume":"8","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2022.101380_bib25","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2022.101380_bib26","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Refined diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.beha.2022.101380_bib27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41375-021-01406-y","article-title":"Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis","volume":"36","author":"Zanotti","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2022.101380_bib28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"Alvarez-Twose","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.beha.2022.101380_bib29","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Updated WHO classification emerging treatment concepts","volume":"129","author":"Valent","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101380_bib30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards at standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.beha.2022.101380_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","article-title":"Mastocytosis: current conception diagnosis and treatment","volume":"81","author":"Escribano","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2022.101380_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state-of-the-art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expet Rev Hematol"},{"key":"10.1016\/j.beha.2022.101380_bib33","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0091-6749(89)90097-3","article-title":"A double-blind, placebo controlled crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis","volume":"83","author":"Kettelhut","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.beha.2022.101380_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromlyn sodium in the management of systolic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.beha.2022.101380_bib35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101380_bib36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","article-title":"Survey of Aspirin administration in systemic mastocytosis","volume":"88","author":"Butterfield","year":"2009","journal-title":"Prostag Other Lipid Mediat"},{"key":"10.1016\/j.beha.2022.101380_bib37","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaci.2007.10.014","article-title":"Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy","author":"Bonadonna","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.beha.2022.101380_bib38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaip.2013.06.014","article-title":"Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety and practical considerations","volume":"1","author":"Bonadonna","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.beha.2022.101380_bib39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omaluzimab prevents anaphylaxis and improves symptoms in systemic mastocytosis; efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.beha.2022.101380_bib40","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omaluzomab in the treatment of adult patients with mastocytosis: a systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.beha.2022.101380_bib41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5414\/ALX02196E","article-title":"Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis","volume":"5","author":"G\u00fclsen","year":"2021","journal-title":"Allergol Select"},{"key":"10.1016\/j.beha.2022.101380_bib42","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladrabine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101380_bib43","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.patbio.2004.04.012","article-title":"Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature","volume":"52","author":"Simon","year":"2004","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.beha.2022.101380_bib44","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2022.101380_bib45","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s10067-006-0369-0","article-title":"Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis","volume":"26","author":"Laroche","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.beha.2022.101380_bib46","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101380_bib47","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2022.101380_bib48","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.beha.2022.101380_bib49","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"volume":"vol. 102","year":"2017","author":"Reiter","key":"10.1016\/j.beha.2022.101380_bib50"},{"key":"10.1016\/j.beha.2022.101380_bib51","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2022.101380_bib52","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2022.101380_bib53","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2021-150872","article-title":"Effective Control of advanced systemic mastocytosis with Avapritinib: mutational analysis from Explorer clinical study","volume":"138","author":"Deininger","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101380_bib54","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41375-022-01615-z","article-title":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","volume":"36","author":"Reiter","year":"2022","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2022.101380_bib55","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1182\/blood-2021-145928","article-title":"A phase 2 study of Bezuclastinib (CGT9486), an oral, selective, and potent KIT D816V inhibitor, in adult patients with advanced systemic mastocytosis (AdvSM)","volume":"138","author":"Gotlib","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101380_bib56","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2022.101380_bib57","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis","volume":"22","author":"Ustin","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.beha.2022.101380_bib58","article-title":"NCCN clinical practice guidelines in oncology 2018","volume":"16","author":"Gotlib","year":"2019","journal-title":"Oncology"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2022.101380_bib59","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1182\/blood-2021-146873","article-title":"Efficacy of avapritinib in patients with advanced systemic mastocytosis: hematologic and bone marrow responses from the phase 2 open-label, single-arm, pathfinder study","author":"George","year":"2021","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2022.101380_bib60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-137413","article-title":"Pure pathologic response is associated with improved overall survival in patients with advanced systemic mastocytosis receiving avapritinib in the phase I EXPLORER study","volume":"136","author":"Gotlib","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2022.101380_bib61","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/j.jaip.2022.05.034","article-title":"Proposed European competence network on mastocytosis-American initiative in mast cell diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis","volume":"10","author":"Gotlib","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692622000354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692622000354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:07:42Z","timestamp":1761498462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692622000354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1521692622000354"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2022.101380","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2022.101380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101380"}}